-
Top 4 Small-Cap Stocks In The Biotechnology Industry With The Lowest PEG Ratio
Tuesday, October 22, 2013 - 4:29am | 115Below are the top small-cap biotechnology stocks on the NYSE and the NASDAQ in terms of PEG ratio. Idenix Pharmaceuticals (NASDAQ: IDIX) has a PEG ratio of 0.11. Idenix's trailing-twelve-month revenue is $33.54 million. Exelixis (NASDAQ: EXEL) has a PEG ratio of 0.17. Exelixis had $351.97 million...
-
Benzinga's Top Pre-Market Losers
Wednesday, October 9, 2013 - 8:20am | 135Ariad Pharmaceuticals (NASDAQ: ARIA) dipped 56.83% to $7.40 in the pre-market session after the company reported that it is pausing patient enrollment in studies of Iclusig. CytRx (NASDAQ: CYTR) dipped 18.25% to $2.24 after the company priced its underwritten public offering of 10.0 million shares...
-
Lexicon Pilot Study of Telotristat Etiprate In Ulcerative Colitis Achieves Primary Objective Demonstrating Safety, Tolerabilty
Wednesday, October 9, 2013 - 6:05am | 212Lexicon Pharmaceuticals (NASDAQ: LXRX) today announced top-line results from a pilot study exploring the use of telotristat etiprate in ulcerative colitis. Telotristat etiprate, a serotonin synthesis inhibitor, is currently in Phase 3 development for carcinoid syndrome, a condition caused by...
-
Morning Market Movers
Tuesday, October 1, 2013 - 9:47am | 114Edgen Group (NYSE: EDG) rose 56.45% to $11.89 after Sumitomo Corporation announced its plans to acquire Edgen Group. Lexicon Pharmaceuticals (NASDAQ: LXRX) moved up 30.73% to $3.11 after the company achieved positive results in type 2 diabetes patients with renal impairment. Myriad Genetics (...
-
Benzinga's Top Pre-Market Gainers
Tuesday, October 1, 2013 - 8:39am | 137Lexicon Pharmaceuticals (NASDAQ: LXRX) shares gained 26.89% to $3.02 in the pre-market session. Lexicon Pharma achieved positive results in type 2 diabetes patients with renal impairment. Myriad Genetics (NASDAQ: MYGN) surged 11.06% to $26.10 in the pre-market session. Myriad Genetics reported...
-
Lexicon Pharma Reports Results from Trial of LX4211, Says Met Primary Goal, Says There Were No Serious Adverse Events
Tuesday, October 1, 2013 - 6:48am | 393Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that LX4211, a first-in-class, dual inhibitor of sodium glucose transporters 1 and 2 (SGLT1 and SGLT2), successfully met the primary endpoint of reducing post-prandial glucose, in a study of patients with type 2 diabetes and moderate to...
-
Kilroy Realty Acquires Premier Del Mar Office Campus for Approximately $126M
Thursday, September 19, 2013 - 7:20pm | 140Kilroy Realty Corporation (NYSE: KRC) today said it has completed the purchase of a 13.8 acre Class A office campus in the premier, coastal Del Mar sub-market of San Diego for approximately $126 million. The campus, known as The Heights, includes a three-story office...
-
Morning Market Losers
Tuesday, September 10, 2013 - 10:24am | 103Model N (NYSE: MODN) dropped 31.57% to $10.08 on downbeat FY14 forecast. JP Morgan downgraded the stock from “overweight” to “neutral.” Neurocrine Biosciences (NASDAQ: NBIX) plummeted 29.82% to $11.72 after the company reported Phase IIb results Of VMAT2 Inhibitor NBI-98854 for treatment of...
-
Benzinga's Top Pre-Market Losers
Tuesday, September 10, 2013 - 8:14am | 119Neurocrine Biosciences (NASDAQ: NBIX) shares dropped 27.25% to $12.15 in pre-market trading after the company reported Phase IIb results Of VMAT2 Inhibitor NBI-98854 for treatment of tardive dyskinesia. ChemoCentryx (NASDAQ: CCXI) dipped 15.25% to $7 in the pre-market session after the company...
-
Neurocrine Announces Negative Phase IIb Results Of VMAT2 Inhibitor NBI-98854 For Treatment Of Tardive Dyskinesia; Company To Host Conference Call And Webcast Monday, September 9th At 5:00PM ET
Monday, September 9, 2013 - 4:03pm | 2166Neurocrine Biosciences (NASDAQ: NBIX) announced today that the 50mg dose of NBI-98854, a small molecule VMAT2 inhibitor in development for tardive dyskinesia, did not meet the primary endpoint in the Phase IIb Kinect study while the 100mg dose showed a statistical and clinically significant...
-
Ligand Enters Global License Agreement with CURx Pharmaceuticals for Captisol-Enabled Topiramate Injection
Wednesday, August 14, 2013 - 8:04am | 888Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces it has entered a global license agreement with CURx Pharmaceuticals, Inc. for the development and commercialization of Ligand's Captisol-enabled™ Topiramate Injection for the treatment of partial onset or primary generalized tonic-clonic...
-
Maxygen Reports Shareholder Approval of Dissolution, Initial Liquidating Distribution of $2.50/Share
Monday, August 12, 2013 - 6:06pm | 279Maxygen, Inc. (Nasdaq: MAXY), today announced that at the company's annual meeting, held earlier today, the shareholders of Maxygen voted to approve the liquidation and dissolution of the company. As contemplated in connection with the approval of the dissolution, the company's Board of Directors...
-
Lexicon Pharmaceuticals Provides Clinical Pipeline Update
Tuesday, July 30, 2013 - 6:24am | 155Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX), a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, today updated its drug development progress and reported financial results for the three and six months ended June 30, 2013. "We have continued...
-
Ligand Receives FDA Orphan Designation for Captisol-Enabled Topiramate Injection
Friday, July 26, 2013 - 6:37am | 131Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that the U.S. Food and Drug Administration (FDA) has granted orphan-drug designation for its proprietary Captisol-enabled™ Topiramate Injection for the treatment of partial onset or primary generalized tonic-...
-
Ligand Pharma Announces License Deal with Ethicor for Oral Lasofoxifene
Wednesday, July 24, 2013 - 8:31am | 112Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces the signing of a license agreement with Ethicor Pharma Ltd. for the manufacture and distribution of the oral formulation of lasofoxifene in the European Economic Area, Switzerland and the Indian Subcontinent. Under the terms of the...